Pharmacovigilance
AI Led Pharmacovigilance Transformation in Life Sciences
A significant uptick in the number of drugs receiving approvals, combined with increased media and patient scrutiny, is sharpening the focus on Drug Safety.
To lead in this scenario, Life Sciences companies need to recaliberate to meet the surging volumes of data, evolving regulations, increasingly discerning patients and difficulties in Adverse Drug Reaction (ADR) reporting.
A significant uptick in the number of drugs receiving approvals, combined with
increased media and patient scrutiny, is sharpening the focus on Drug Safety.
To lead in this scenario, Life Sciences companies need to recaliberate to meet the
surging volumes of data, evolving regulations, increasingly discerning patients and
difficulties in Adverse Drug Reaction (ADR) reporting.